- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03078400
Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer
An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used In Combination With Paclitaxel In Patients With Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer
Study Overview
Detailed Description
This is an open-label 2-arm trial. Eligible subjects will be screened and enrolled sequentially into 1 of 2 Arms:
Arm I: N=6 to 12 subjects, Safety Phase
- Cohort 1 SPL-108 x 1 injection daily + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles
- Cohort 2 SPL-108 BID + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles
For Arm I, at least 1 week will elapse between Dose 1 for each subject.
In Cohort 1, 3 subjects will be enrolled: if 1 dose-limiting toxicity (DLT) occurs, 3 subjects will be added at this dose level; if 0/3 or 1/6 DLTs occur, Cohort 2 will initiate enrolling subjects; if 2 or more DLTs occur at this dose level, subjects will not be enrolled in Cohort 2 and the trial will be terminated.
In Cohort 2, 3 subjects will be enrolled: if 1 DLT occurs, 3 subjects will be added at this dose level; if 0/3 or 1/6 DLTs occur, Arm II will initiate enrolling subjects at the SPL-108 BID dose; if 2 or more DLTs occur, Arm II will initiate enrolling subjects at the SPL-108 dose one time each day.
Arm II: N=up to 12, Exploratory Expansion Phase
• Cohort 3: SPL-108 daily dose (to be determined in Arm I) + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles.
A Safety Committee will meet at the end of each Arm I Cohort as well as periodically to review safety data and make recommendations for trial progression. The primary efficacy outcome, Response Evaluation Criteria in Solid Tumors Committee (RECIST 1.1) criteria, will be assessed on Day 15 of Cycles 2, 4, and 6.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Females ≥18 years of age
- Platinum-resistant recurrent or metastatic epithelial ovarian carcinoma
- Positivity on CD44 assay as defined by strong (+++) or moderate (++) staining in 20% or more of the tumor tissue/stroma as obtained by biopsy or paracentesis
- Status post first-line therapy with definitive surgery (which provided tissue for pathologic diagnosis) and chemotherapy
- Original diagnosis has been confirmed through a histopathologic review of the primary tumor slides by an expert pathologist at the Principal Investigator's institution
- Disease has progressed or recurred during or less than 6 months after platinum-based chemotherapy at some point during the subject's course.
- No more than 3 prior regimens of cytotoxic chemotherapy unless approved by the sponsor (Note: all platinum-containing regimens are not to be counted separately but are considered to be a single regimen for the purposes of this criterion)
- Measurable disease by RECIST 1.1 criteria
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2
- Women with childbearing potential and partners must both use effective contraception during the study and for 3 months after the last dose
- Life expectancy of at least 6 months
- Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent before the first study-specific procedure
Exclusion Criteria:
- Treatment with cytotoxic chemotherapy for malignancies other than ovarian cancer within the past 5 years
- Fewer than 28 days before Cycle 1 Day 1 since any prior chemotherapy (less than 42 days in the case of mitomycin or a nitrosourea)
- Fewer than 28 days before Cycle 1 Day 1 since administration of hormonal or biological anti-neoplastic agents
- Concomitant use of other cytotoxic or cytostatic drugs other than PTX
Abnormal clinical laboratory values within 14 days prior to initiation of dosing, as indicated by:
- Hemoglobin level <9.0 gm/L
- Platelet count <100,000/mm3
- Granulocyte count <1500/mm3
- Serum creatinine level ≥2.5 mg/dL (221 μmol/L)
- Liver aminotransferase levels greater than 3 times the laboratory's upper limit of normal (greater than 5 times the laboratory's upper limit of normal if the liver is known to be involved with tumor)
- Contraindication to the use of PTX
- Pregnancy or breast-feeding at time of Screening and throughout the study.
- Active, uncontrolled infection
- Participation in another investigational drug trial concurrently or within 30 days of Cycle 1 Day 1, or a vaccine trial within 90 days of Cycle 1 Day 1
- Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the trial, and/or compromise the objectives of the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Safety Phase
Six to 12 subjects
|
Subcutaneous injection of 150 mg administered either one time or two times per day.
|
EXPERIMENTAL: Exploratory Expansion Phase
Up to 12 subjects • Cohort 3: SPL-108 daily dose (to be determined in Arm I) + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles. |
Subcutaneous injection of 150 mg administered either one time or two times per day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events (Safety)
Time Frame: Until dose-limiting toxicity, disease progression or 6 months
|
Includes adverse events, laboratory data, physical examination findings, vital signs, weight and ECOG Performance Status
|
Until dose-limiting toxicity, disease progression or 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response to Investigational Product
Time Frame: Until dose-limiting toxicity, disease progression or 6 months
|
Objective response (OR) through imaging assessments
|
Until dose-limiting toxicity, disease progression or 6 months
|
Response to Investigational Product
Time Frame: Until dose-limiting toxicity, disease progression or 6 months
|
Objective response (OR) through changes in CA 125 levels
|
Until dose-limiting toxicity, disease progression or 6 months
|
Response to Investigational Product
Time Frame: Until dose-limiting toxicity, disease progression or 6 months
|
Objective response (OR) as assessed through changes in Quality of Life (FACT-O Questionnaire)
|
Until dose-limiting toxicity, disease progression or 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: June Girda, MD, Rutgers Cancer Institute of New Jersey
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
- SPL-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Epithelial Cancer
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Centre Leon BerardCancer Côte d'or registry; Cancer Calvados registryUnknownOvarian Epithelial CancerFrance
-
National Cancer Institute (NCI)CompletedStage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial CancerUnited States
-
National Cancer Institute (NCI)Gynecologic Oncology GroupCompletedFallopian Tube Cancer | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity CancerCanada
-
National Cancer Institute (NCI)CompletedStage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIIA Primary... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnRecurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Recurrent Ovarian Epithelial Cancer | Recurrent Ovarian Germ Cell Tumor | Stage IIIA Ovarian Germ Cell Tumor | Stage IIIB Ovarian Germ Cell... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedFallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma and other conditionsUnited States
-
Life Research Technologies GmbHUnknownOvarian Epithelial CancerAustria, Hungary
Clinical Trials on SPL-108
-
Ganin Fertility CenterCompletedInfertility | Embryonic DevelopmentEgypt
-
Dow Pharmaceutical SciencesCompleted
-
University of California, San FranciscoCompletedProgressive Supranuclear Palsy | Corticobasal Degeneration Syndrome | Progressive Nonfluent Aphasia | Predicted Tauopathies, Including | Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17United States
-
SRI InternationalTaiho Pharmaceutical Co., Ltd.CompletedBreast CancerUnited States
-
University of California, Los AngelesMassachusetts General Hospital; Washington University School of Medicine; University... and other collaboratorsCompleted
-
Allon TherapeuticsCompletedMild Cognitive Impairment, So StatedUnited States
-
Dow Pharmaceutical SciencesCompletedOnychomycosisUnited States, Canada
-
Immune-Onc TherapeuticsRegeneron PharmaceuticalsActive, not recruiting
-
The First Affiliated Hospital with Nanjing Medical...Guangzhou Lupeng Pharmaceutical Company LTD.; Newave Pharmaceutical IncRecruitingChronic Lymphocytic Leukemia | Non-Hodgkin LymphomaChina
-
Immune-Onc TherapeuticsRecruitingAdvanced Solid TumorChina